Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI-Powered ECG could cut unnecessary heart tests

NCT ID NCT07757425

Diagnosis Sponsor: Jamil Mayet Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This trial is testing whether an artificial intelligence-enhanced electrocardiogram (AI-ECG) can help doctors quickly and safely identify which people with non-cardiac chest pain are truly low risk. Half of the participants will receive the AI-ECG in addition to standard care, while the other half will receive standard care alone. The study aims to see if the AI-ECG can reduce unnecessary tests, lower healthcare costs, and speed up diagnosis and reassurance, without compromising patient safety.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AI-enhanced electrocardiogram (AI-ECG) as a diagnostic test
What this could lead to
If effective, this AI-ECG pathway could reduce unnecessary invasive tests, lower healthcare costs, and provide faster reassurance for many patients with chest pain.
What could go wrong
The AI-ECG is still experimental and may not be as accurate in real-world settings. There is also a risk that relying on it could miss some heart problems, and the trial's results may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 4,000 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Jan 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Our study population will include all patients aged 18 years and older presenting with non-anginal chest pain (chest pain that is not typical to the heart) to 6 rapid access chest pain clinic sites across North West London. Chest pain typicality will be defined using the standardised Rose Angina questionnaire, based on clinical history. Exclusion Criteria: * Patients with typical cardiac (heart-related) chest pain, as defined by the Rose Angina classification * Patients with known moderate or severe stenosis (narrowing) in an epicardial coronary artery (the blood vessels supplying the heart) * Known left ventricular impairment (left ventricular ejection fraction \<50%), otherwise known as heart failure * Left bundle branch block (a significant electrical abnormality of the heart on ECG) * End-stage kidney failure requiring renal replacement therapy such as dialysis or a kidney transplant * Moderate or severe valvular heart disease (serious narrowing or leaking of the heart valves) * Paced rhythm at the time of ECG acquisition (lots of patients with pacemakers will fall into this category, but only if their pacemaker is firing at the time the ECG was taken).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Angina (stable) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Angina, Stable intermediate coronary syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Angina (stable) Chest pain atypical syndrome

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Imperial College NHS Healthcare Trust

    London, London, United Kingdom

  • London North West University Healthcare NHS Trust

    London, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.